Stoke Therapeutics (STOK) Financials

Stoke Therapeutics logo
$26.63 -0.05 (-0.19%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$26.63 0.00 (0.00%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Stoke Therapeutics

Annual Income Statements for Stoke Therapeutics

This table shows Stoke Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-13 -32 -52 -86 -101 -105 -89 -6.89
Consolidated Net Income / (Loss)
-13 -32 -52 -86 -101 -105 -89 -6.89
Net Income / (Loss) Continuing Operations
-13 -32 -52 -86 -101 -105 -89 -6.89
Total Pre-Tax Income
-13 -32 -52 -86 -101 -105 -89 -6.89
Total Operating Income
-13 -36 -53 -86 -104 -115 -101 -21
Total Gross Profit
0.00 0.00 0.00 0.00 12 8.78 37 184
Total Revenue
0.00 0.00 0.00 0.00 12 8.78 37 184
Operating Revenue
0.00 0.00 0.00 0.00 12 8.78 37 184
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
13 36 53 86 117 124 138 205
Selling, General & Admin Expense
4.41 12 21 32 39 41 49 67
Research & Development Expense
8.37 24 32 54 78 82 89 138
Total Other Income / (Expense), net
0.26 3.35 0.80 0.26 3.29 10 12 14
Interest & Investment Income
0.27 3.35 0.70 0.12 3.12 9.91 13 14
Other Income / (Expense), net
-0.01 0.00 0.10 0.14 0.17 0.17 -0.25 -0.05
Basic Earnings per Share
($17.65) ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Weighted Average Basic Shares Outstanding
709.34K 17.97M 33.49M 36.74M 38.90M 43.99M 54.01M 59.22M
Diluted Earnings per Share
($17.65) ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Weighted Average Diluted Shares Outstanding
709.34K 17.97M 33.49M 36.74M 38.90M 43.99M 54.01M 59.22M
Weighted Average Basic & Diluted Shares Outstanding
709.34K 17.97M 33.49M 36.74M 44.15M 46.30M 54.08M 59.15M

Quarterly Income Statements for Stoke Therapeutics

This table shows Stoke Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Total Costs & Expenses
- - - - - - 54 - - - 89
Net Income / (Loss) Attributable to Common Shareholders
-26 -26 -26 -11 113 -23 -38 -58 -50 -62 -74
Consolidated Net Income / (Loss)
-26 -26 -26 -10 113 -23 -38 -58 -50 -62 -74
Net Income / (Loss) Continuing Operations
-26 -26 -26 -10 113 -23 -38 -58 -50 -62 -74
Total Pre-Tax Income
-26 -26 -26 -10 114 -23 -40 -58 -50 -62 -74
Total Operating Income
-28 -29 -30 -14 111 -27 -43 -61 -53 -65 -77
Total Gross Profit
4.22 4.83 4.89 23 159 14 11 1.40 6.23 9.33 11
Total Revenue
4.22 4.83 4.89 23 159 14 11 1.40 6.23 9.33 11
Operating Revenue
4.22 4.83 4.89 23 159 14 11 1.40 6.23 9.33 11
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
33 34 35 36 47 41 54 63 60 75 89
Selling, General & Admin Expense
10 13 13 13 15 15 16 21 20 25 29
Research & Development Expense
22 21 22 23 33 26 38 42 40 50 60
Total Other Income / (Expense), net
2.00 3.65 3.57 3.17 2.92 3.82 3.47 3.51 3.42 3.81 3.67
Interest & Investment Income
2.43 3.70 3.55 2.97 2.89 3.79 3.46 3.62 3.40 3.50 3.67
Other Income / (Expense), net
-0.43 -0.05 0.03 0.20 0.03 0.03 0.00 -0.11 0.02 0.31 0.01
Income Tax Expense
0.00 0.00 0.00 - 1.28 0.00 -1.28 - 0.00 0.00 0.00
Basic Earnings per Share
($0.57) ($0.46) ($0.47) ($0.15) $1.95 ($0.40) ($0.65) ($1.02) ($0.79) ($0.93) ($1.08)
Weighted Average Basic Shares Outstanding
46.25M 55.77M 56.34M 54.01M 57.86M 58.35M 58.61M 59.22M 63.06M 66.02M 68.36M
Diluted Earnings per Share
($0.57) ($0.46) ($0.47) ($0.15) $1.90 ($0.40) ($0.65) ($0.97) ($0.79) ($0.93) ($1.08)
Weighted Average Diluted Shares Outstanding
46.25M 55.77M 56.34M 54.01M 59.40M 58.35M 58.61M 59.22M 63.06M 66.02M 68.36M
Weighted Average Basic & Diluted Shares Outstanding
52.12M 52.65M 52.97M 54.08M 54.60M 54.80M 57.12M 59.15M 62.28M 64.53M 65.41M

Annual Cash Flow Statements for Stoke Therapeutics

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
104 117 65 -142 -31 78 -63 -44
Net Cash From Operating Activities
-11 -31 -42 -67 -32 -81 -87 46
Net Cash From Continuing Operating Activities
-11 -31 -42 -67 -32 -81 -87 46
Net Income / (Loss) Continuing Operations
-13 -32 -52 -86 -101 -105 -89 -6.89
Consolidated Net Income / (Loss)
-13 -32 -52 -86 -101 -105 -89 -6.89
Depreciation Expense
0.21 0.45 0.89 0.97 1.55 2.47 2.18 1.77
Amortization Expense
- - 0.00 0.14 -0.21 -0.33 -1.64 -1.13
Non-Cash Adjustments To Reconcile Net Income
0.25 1.93 6.81 18 25 28 30 35
Changes in Operating Assets and Liabilities, net
1.09 -1.11 2.33 0.05 43 -6.03 -28 16
Net Cash From Investing Activities
-0.93 -1.63 -1.05 -76 -46 106 -107 -187
Net Cash From Continuing Investing Activities
-0.93 -1.63 -1.05 -76 -46 106 -107 -187
Purchase of Property, Plant & Equipment
-0.94 -1.64 -1.05 -1.20 -3.96 -1.62 -0.20 -0.67
Purchase of Investments
- - 0.00 -87 -201 0.00 -167 -323
Sale and/or Maturity of Investments
- - 0.00 12 159 108 60 137
Net Cash From Financing Activities
116 150 108 1.28 46 53 131 97
Net Cash From Continuing Financing Activities
116 150 108 1.28 46 53 131 97
Issuance of Common Equity
0.00 152 106 0.51 46 53 0.53 1.00
Other Financing Activities, net
0.02 0.32 2.84 0.78 0.49 0.37 131 96
Cash Interest Paid
- - - - - - 0.00 0.00

Quarterly Cash Flow Statements for Stoke Therapeutics

This table details how cash moves in and out of Stoke Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
-13 15 -43 -22 147 -173 -18 0.83 74 -46 -2.73
Net Cash From Operating Activities
-25 -17 -22 -23 132 -25 -30 -30 -61 -57 -63
Net Cash From Continuing Operating Activities
-25 -17 -22 -23 132 -25 -30 -30 -61 -57 -63
Net Income / (Loss) Continuing Operations
-26 -26 -26 -10 113 -23 -38 -58 -50 -62 -74
Consolidated Net Income / (Loss)
-26 -26 -26 -10 113 -23 -38 -58 -50 -62 -74
Depreciation Expense
0.56 0.55 0.54 0.53 0.48 0.45 0.44 0.41 0.44 0.46 0.46
Amortization Expense
-0.02 -0.29 -0.55 -0.78 -0.49 0.53 -0.62 -0.55 -0.37 -0.37 -0.35
Non-Cash Adjustments To Reconcile Net Income
5.96 7.99 8.07 7.72 7.35 8.21 9.27 11 9.36 11 12
Changes in Operating Assets and Liabilities, net
-4.69 -0.03 -3.24 -20 12 -11 -1.12 17 -20 -6.54 -0.82
Net Cash From Investing Activities
9.99 -88 -30 0.82 14 -148 9.09 -61 51 9.02 -10
Net Cash From Continuing Investing Activities
9.99 -88 -30 0.82 14 -148 9.09 -61 51 9.02 -10
Purchase of Property, Plant & Equipment
-0.01 -0.05 -0.10 -0.04 -0.15 -0.15 -0.13 -0.23 -0.35 -1.98 -2.85
Purchase of Investments
0.00 - -50 -29 -19 -182 -24 -98 -9.85 -36 -58
Sale and/or Maturity of Investments
10 - 20 30 33 33 33 37 61 47 51
Net Cash From Financing Activities
1.72 121 8.16 0.57 1.37 0.55 3.12 92 84 1.91 70
Net Cash From Continuing Financing Activities
1.72 121 8.16 0.57 1.37 0.55 3.12 92 84 1.91 70
Issuance of Common Equity
1.47 - 8.02 0.00 0.37 - 0.63 - 81 - 67
Other Financing Activities, net
0.25 121 0.14 0.57 1.00 0.55 2.49 92 3.21 1.91 3.53

Annual Balance Sheets for Stoke Therapeutics

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
108 229 298 239 256 228 272 418
Total Current Assets
106 226 294 229 244 215 233 306
Cash & Equivalents
105 222 287 145 114 191 128 84
Short-Term Investments
- - 0.00 75 116 9.95 89 200
Note & Lease Receivable
0.20 0.28 0.01 0.13 0.59 0.06 0.70 1.97
Accounts Receivable
- - - - - - 1.67 5.94
Prepaid Expenses
0.55 3.28 6.44 6.94 11 11 11 8.74
Other Current Assets
- 0.00 0.18 2.33 2.96 2.56 2.30 4.39
Plant, Property, & Equipment, net
1.19 2.51 2.68 4.14 6.68 5.82 3.91 3.15
Total Noncurrent Assets
0.20 0.21 1.32 5.51 5.32 7.18 35 110
Long-Term Investments
- - - - - 0.00 30 106
Other Noncurrent Operating Assets
0.20 0.21 1.32 5.51 5.32 7.18 5.07 3.33
Total Liabilities & Shareholders' Equity
108 229 298 239 256 228 272 418
Total Liabilities
2.47 4.32 12 21 71 69 43 66
Total Current Liabilities
2.47 4.10 11 17 31 31 40 58
Accounts Payable
1.07 0.75 1.50 2.39 0.77 1.70 2.50 4.94
Accrued Expenses
1.40 3.35 9.93 15 16 14 19 41
Current Deferred Revenue
- - - 0.00 15 15 19 12
Total Noncurrent Liabilities
0.00 0.22 0.42 3.95 40 38 2.48 8.10
Noncurrent Deferred Revenue
- - - 0.00 37 33 0.00 6.96
Other Noncurrent Operating Liabilities
0.00 0.22 0.42 3.95 2.97 4.88 2.48 1.14
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
105 224 286 218 185 160 229 352
Total Preferred & Common Equity
105 224 286 218 185 160 229 352
Total Common Equity
105 224 286 218 185 160 229 352
Common Stock
131 282 396 414 483 561 720 850
Retained Earnings
-26 -58 -110 -196 -297 -402 -491 -498
Accumulated Other Comprehensive Income / (Loss)
- - 0.00 -0.17 -1.18 -0.02 -0.15 0.54

Quarterly Balance Sheets for Stoke Therapeutics

This table presents Stoke Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
257 240 205 308 293 407 385 360 443 394 407
Total Current Assets
246 230 193 297 254 376 270 272 367 323 354
Cash & Equivalents
192 190 179 193 150 275 101 83 156 110 107
Short-Term Investments
39 25 0.00 89 89 83 146 165 188 183 212
Note & Lease Receivable
0.14 0.10 0.01 0.31 0.69 0.61 1.62 1.59 1.69 1.54 1.53
Accounts Receivable
- - - - - - - 9.25 4.45 7.18 8.54
Prepaid Expenses
11 11 11 10 9.84 13 14 7.75 10 15 18
Other Current Assets
3.70 4.27 3.96 4.29 3.81 5.04 6.87 5.54 6.88 6.31 7.56
Plant, Property, & Equipment, net
6.47 6.22 5.28 4.77 4.33 3.61 3.34 3.08 3.40 4.83 8.21
Total Noncurrent Assets
4.22 3.65 6.63 5.99 35 28 111 85 73 67 44
Long-Term Investments
- - - - 30 23 107 80 67 62 40
Other Noncurrent Operating Assets
4.22 3.65 6.63 5.99 5.42 4.55 3.94 4.43 5.72 5.10 4.46
Total Liabilities & Shareholders' Equity
257 240 205 308 293 407 385 360 443 394 407
Total Liabilities
67 67 65 65 61 57 50 52 48 48 54
Total Current Liabilities
22 25 36 44 50 45 39 42 41 42 49
Accounts Payable
1.56 3.08 2.10 3.95 2.49 2.19 4.31 5.87 6.84 4.79 4.03
Accrued Expenses
12 13 13 15 16 24 26 30 24 29 39
Current Deferred Revenue
8.06 8.74 21 26 32 18 8.75 5.76 10 8.52 6.36
Total Noncurrent Liabilities
45 42 29 21 11 12 11 10 7.59 6.49 5.13
Noncurrent Deferred Revenue
43 41 25 17 8.29 10 9.63 8.56 6.60 5.65 4.45
Other Noncurrent Operating Liabilities
1.63 0.96 4.21 3.61 3.05 1.87 1.26 1.87 0.99 0.84 0.68
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
190 173 140 243 232 350 335 308 395 346 353
Total Preferred & Common Equity
190 173 140 243 232 350 335 308 395 346 353
Total Common Equity
190 173 140 243 232 350 335 308 395 346 353
Common Stock
541 548 569 697 712 728 736 747 943 955 1,037
Retained Earnings
-350 -375 -428 -454 -480 -378 -401 -440 -548 -609 -683
Accumulated Other Comprehensive Income / (Loss)
-0.38 -0.15 0.00 -0.02 0.17 -0.10 0.10 0.45 -0.12 -0.54 -1.05

Annual Metrics And Ratios for Stoke Therapeutics

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
0.00 32,729,777.00 33,470,262.00 36,790,993.00 - - - 57,117,150.00
DEI Adjusted Shares Outstanding
0.00 32,729,777.00 33,470,262.00 36,790,993.00 - - - 57,117,150.00
DEI Earnings Per Adjusted Shares Outstanding
0.00 -0.99 -1.56 -2.33 - - - -0.12
Growth Metrics
- - - - - - - -
Profitability Metrics
- - - - - - - -
Net Operating Profit after Tax (NOPAT)
-8.95 -25 -37 -60 -73 -80 -71 -14
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -50.35% -30.98% -4.09%
Earnings before Interest and Taxes (EBIT)
-13 -36 -53 -86 -104 -115 -102 -21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -35 -52 -85 -103 -112 -101 -20
Valuation Ratios
- - - - - - - -
Leverage & Solvency
- - - - - - - -
Liquidity Ratios
- - - - - - - -
Cash Flow Metrics
- - - - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -27 -34 -59 -30 -83 -95 6.78
Efficiency Ratios
- - - - - - - -
Capital & Investment Metrics
- - - - - - - -
Invested Capital
-0.33 1.96 -1.23 -2.03 -45 -42 -18 -39
Increase / (Decrease) in Invested Capital
0.00 2.29 -3.19 -0.80 -43 2.92 24 -21
Book Value per Share
$148.12 $6.86 $8.55 $5.92 $4.69 $3.57 $4.32 $6.17
Tangible Book Value per Share
$148.12 $6.86 $8.55 $5.92 $4.69 $3.57 $4.32 $6.17
Total Capital
105 224 286 218 185 160 229 352
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-105 -222 -287 -220 -230 -201 -247 -391
Capital Expenditures (CapEx)
0.93 1.63 1.05 1.20 3.96 1.62 0.20 0.67
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.72 -0.54 -4.80 -7.73 -17 -17 -24 -37
Debt-free Net Working Capital (DFNWC)
104 222 283 212 213 185 193 248
Net Working Capital (NWC)
104 222 283 212 213 185 193 248
Net Nonoperating Expense (NNE)
3.57 7.35 15 26 28 24 18 -7.53
Net Nonoperating Obligations (NNO)
-105 -222 -287 -220 -230 -201 -247 -391
Total Depreciation and Amortization (D&A)
0.21 0.45 0.89 1.12 1.34 2.14 0.54 0.64
Earnings Adjustments
- - - - - - - -
Adjusted Basic Earnings per Share
$0.00 ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Adjusted Weighted Average Basic Shares Outstanding
0.00 32.94M 36.66M 37.36M 38.90M 43.99M 54.01M 59.22M
Adjusted Diluted Earnings per Share
$0.00 ($1.80) ($1.56) ($2.34) ($2.60) ($2.38) ($1.65) ($0.12)
Adjusted Weighted Average Diluted Shares Outstanding
0.00 32.94M 36.66M 37.36M 38.90M 43.99M 54.01M 59.22M
Adjusted Basic & Diluted Earnings per Share
$0.00 ($1.80) ($1.56) ($2.34) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 17.97M 33.49M 36.74M 44.15M 46.30M 54.08M 59.15M
Normalized Net Operating Profit after Tax (NOPAT)
-8.95 -25 -37 -60 -73 -80 -71 -14
Debt Service Ratios
- - - - - - - -
Payout Ratios
- - - - - - - -

Quarterly Metrics And Ratios for Stoke Therapeutics

This table displays calculated financial ratios and metrics derived from Stoke Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
- - - - 54,077,739.00 54,596,924.00 54,797,418.00 57,117,150.00 59,150,790.00 62,281,655.00 64,526,242.00
DEI Adjusted Shares Outstanding
- - - - 54,077,739.00 54,596,924.00 54,797,418.00 57,117,150.00 59,150,790.00 62,281,655.00 64,526,242.00
DEI Earnings Per Adjusted Shares Outstanding
- - - - 2.09 -0.43 -0.70 -1.01 -0.85 -0.99 -1.14
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-18.17% 294.72% 47.94% 707.35% 3,661.12% 186.01% 117.25% - -96.07% -32.51% 5.86%
EBITDA Growth
-17.66% 11.07% -12.38% 52.74% 493.66% 9.72% -44.29% - -147.93% -147.28% -78.46%
EBIT Growth
-16.85% 11.53% -10.23% 54.46% 486.35% 7.21% -43.75% - -147.99% -138.78% -79.42%
NOPAT Growth
-14.91% 11.79% -10.17% 53.85% 653.84% 6.96% -43.62% - -133.99% -139.67% -79.42%
Net Income Growth
-16.98% 16.18% -7.69% 61.12% 527.99% 8.61% -45.09% - -144.30% -162.39% -92.05%
EPS Growth
-7.55% 33.33% 14.55% 75.41% 433.33% 13.04% -38.30% - -141.58% -132.50% -66.15%
Operating Cash Flow Growth
-15.03% 19.83% -25.22% -12.32% 636.62% -45.46% -40.49% - -145.96% -122.58% -106.43%
Free Cash Flow Firm Growth
29.99% 33.81% -0.71% -42.25% 575.35% -70.93% -82.60% - -150.51% -48.91% -46.37%
Invested Capital Growth
4.05% 4.62% 11.04% 57.50% 20.72% 48.93% 44.71% - 46.73% 56.34% 69.78%
Revenue Q/Q Growth
50.52% 14.59% 1.30% 362.08% 601.20% -91.29% -23.05% - 344.29% 49.70% 20.70%
EBITDA Q/Q Growth
2.58% -3.08% -2.92% 54.27% 911.46% -123.64% -64.50% - 13.57% -21.95% -18.72%
EBIT Q/Q Growth
2.52% -2.05% -1.99% 55.12% 927.03% -124.51% -57.99% - 13.24% -21.95% -18.72%
NOPAT Q/Q Growth
4.11% -3.42% -2.25% 54.49% 1,250.75% -117.37% -57.84% - 13.06% -22.48% -18.17%
Net Income Q/Q Growth
2.17% 2.57% -2.86% 60.34% 1,176.88% -120.80% -63.30% - 13.69% -23.23% -19.52%
EPS Q/Q Growth
6.56% 19.30% -2.17% 68.09% 1,366.67% -121.05% -62.50% - 18.56% -17.72% -16.13%
Operating Cash Flow Q/Q Growth
-18.97% 28.86% -23.68% -7.30% 668.39% -119.28% -19.45% - -98.93% 6.60% -10.78%
Free Cash Flow Firm Q/Q Growth
9.12% -4.52% -14.10% -31.25% 403.68% -137.58% -21.89% - -131.08% -10.80% -19.81%
Invested Capital Q/Q Growth
8.58% -2.90% 5.68% 52.10% -70.52% 33.71% -2.11% - 58.03% 45.67% 29.32%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
EBITDA Margin
-670.33% -603.00% -612.63% -60.63% 70.16% -190.34% -406.89% - -856.09% -697.39% -685.96%
Operating Margin
-672.96% -607.37% -613.06% -60.38% 70.15% -197.58% -405.30% - -857.57% -701.65% -686.94%
EBIT Margin
-683.11% -608.36% -612.48% -59.49% 70.17% -197.38% -405.27% - -857.28% -698.35% -686.89%
Profit (Net Income) Margin
-625.57% -531.88% -540.05% -46.35% 71.19% -169.96% -360.68% - -802.75% -660.78% -654.32%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 98.88% 100.00% 96.77% - 100.00% 100.00% 100.00%
Interest Burden Percent
91.58% 87.43% 88.17% 77.91% 102.60% 86.11% 91.96% - 93.64% 94.62% 95.26%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 1.12% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Return on Equity (ROE)
-61.29% -47.85% -52.06% -45.80% 20.50% 18.17% 15.02% - -45.58% -61.10% -73.62%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-22.01% -32.66% -38.46% -8.70% 43.77% -113.99% -255.01% - -64.70% -49.50% -50.53%
Return on Assets (ROA)
-20.15% -28.55% -33.91% -6.78% 44.41% -98.15% -226.95% - -60.58% -46.83% -48.14%
Return on Common Equity (ROCE)
-61.29% -47.85% -52.06% -45.80% 20.50% 18.17% 15.02% - -45.58% -61.10% -73.62%
Return on Equity Simple (ROE_SIMPLE)
-77.33% -42.67% -45.43% 0.00% 14.36% 0.00% 0.00% - 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-20 -21 -21 -9.56 110 -19 -30 -43 -37 -46 -54
NOPAT Margin
-471.07% -425.16% -429.14% -42.27% 69.37% -138.31% -283.71% - -600.30% -491.16% -480.86%
Net Nonoperating Expense Percent (NNEP)
-3.01% -2.01% -2.24% -0.41% 1.03% -1.37% -2.74% - -3.19% -4.46% -5.68%
Return On Investment Capital (ROIC_SIMPLE)
- - - -4.17% 31.42% -5.71% -9.79% -12.20% -9.47% -13.25% -15.35%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
242.41% 269.86% 259.34% 56.80% 9.24% 110.46% 150.74% - 320.66% 270.81% 255.34%
R&D to Revenue
530.55% 437.51% 453.72% 103.58% 20.61% 187.12% 354.55% - 636.91% 530.84% 531.59%
Operating Expenses to Revenue
772.96% 707.37% 713.06% 160.38% 29.85% 297.58% 505.30% - 957.57% 801.65% 786.94%
Earnings before Interest and Taxes (EBIT)
-29 -29 -30 -13 111 -27 -43 -62 -53 -65 -77
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-28 -29 -30 -14 111 -26 -43 -62 -53 -65 -77
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.45 2.90 2.79 2.55 1.03 1.85 4.18 - 4.88 5.90 4.76
Price to Tangible Book Value (P/TBV)
4.45 2.90 2.79 2.55 1.03 1.85 4.18 - 4.88 5.90 4.76
Price to Revenue (P/Rev)
79.69 46.46 38.65 15.98 1.88 3.10 6.26 - 60.04 73.87 59.47
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 7.15 11.81 31.74 - 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 13.98% 8.47% 3.15% - 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
56.93 27.85 22.57 9.23 0.00 1.32 4.66 - 47.22 61.02 46.75
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 6.41 34.28 - 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 6.52 34.94 - 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 6.57 35.27 - 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 4.30 18.15 - 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 12.58 90.48 - 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Financial Leverage
-1.22 -1.19 -1.19 -1.15 -1.14 -1.10 -1.11 - -1.06 -1.04 -1.04
Leverage Ratio
1.38 1.30 1.32 1.29 1.25 1.20 1.21 - 1.14 1.14 1.16
Compound Leverage Factor
1.26 1.14 1.16 1.00 1.28 1.03 1.11 - 1.07 1.08 1.11
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Altman Z-Score
3.36 5.15 4.60 6.53 4.85 7.05 14.05 - 22.70 23.47 16.60
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
5.43 6.67 5.09 5.81 8.41 6.98 6.53 - 8.99 7.69 7.24
Quick Ratio
5.02 6.34 4.81 5.43 8.01 6.45 6.21 - 8.57 7.19 6.72
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-21 -22 -26 -34 102 -38 -47 -22 -52 -57 -68
Operating Cash Flow to CapEx
-204,716.67% -37,993.48% -20,985.44% -55,221.43% 86,728.29% -16,507.79% -23,004.55% - -17,162.04% -2,863.61% -2,198.74%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.03 0.05 0.06 0.15 0.62 0.58 0.63 - 0.08 0.07 0.07
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 3.17
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Fixed Asset Turnover
1.30 2.70 3.17 7.51 42.95 49.28 55.46 - 9.16 6.75 4.99
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 115.09
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 115.09
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
-38 -39 -37 -18 -30 -20 -21 -39 -16 -8.77 -6.20
Invested Capital Turnover
-0.20 -0.38 -0.42 -1.23 -5.57 -6.73 -7.14 - -1.38 -1.91 -2.11
Increase / (Decrease) in Invested Capital
1.61 1.90 4.61 24 7.93 19 17 -21 14 11 14
Enterprise Value (EV)
447 422 378 337 -21 265 959 - 1,515 1,684 1,319
Market Capitalization
625 704 647 584 360 620 1,288 - 1,926 2,038 1,678
Book Value per Share
$3.03 $4.66 $4.41 $4.32 $6.47 $6.13 $5.62 $6.17 $6.68 $5.55 $5.46
Tangible Book Value per Share
$3.03 $4.66 $4.41 $4.32 $6.47 $6.13 $5.62 $6.17 $6.68 $5.55 $5.46
Total Capital
140 243 232 229 350 335 308 352 395 346 353
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-179 -282 -269 -247 -380 -355 -329 -391 -411 -354 -359
Capital Expenditures (CapEx)
0.01 0.05 0.10 0.04 0.15 0.15 0.13 0.23 0.35 1.98 2.85
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-21 -30 -36 -24 -26 -16 -18 -37 -18 -12 -14
Debt-free Net Working Capital (DFNWC)
158 252 204 193 331 231 231 248 326 281 305
Net Working Capital (NWC)
158 252 204 193 331 231 231 248 326 281 305
Net Nonoperating Expense (NNE)
6.51 5.16 5.43 0.92 -2.88 4.37 8.18 15 13 16 20
Net Nonoperating Obligations (NNO)
-179 -282 -269 -247 -380 -355 -329 -391 -411 -354 -359
Total Depreciation and Amortization (D&A)
0.54 0.26 -0.01 -0.26 -0.02 0.97 -0.17 -0.15 0.07 0.09 0.10
Debt-free, Cash-free Net Working Capital to Revenue
-266.39% -195.03% -212.21% -66.40% -13.80% -8.25% -8.56% - -55.08% -44.26% -48.73%
Debt-free Net Working Capital to Revenue
2,010.26% 1,665.99% 1,216.98% 527.15% 173.41% 115.71% 112.20% - 1,015.82% 1,017.14% 1,082.70%
Net Working Capital to Revenue
2,010.26% 1,665.99% 1,216.98% 527.15% 173.41% 115.71% 112.20% - 1,015.82% 1,017.14% 1,082.70%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($0.57) ($0.46) ($0.47) ($0.15) $1.95 ($0.40) ($0.65) ($1.02) ($0.79) ($0.93) ($1.08)
Adjusted Weighted Average Basic Shares Outstanding
46.25M 55.77M 56.34M 54.01M 57.86M 58.35M 58.61M 59.22M 63.06M 66.02M 68.36M
Adjusted Diluted Earnings per Share
($0.57) ($0.46) ($0.47) ($0.15) $1.90 ($0.40) ($0.65) ($0.97) ($0.79) ($0.93) ($1.08)
Adjusted Weighted Average Diluted Shares Outstanding
46.25M 55.77M 56.34M 54.01M 59.40M 58.35M 58.61M 59.22M 63.06M 66.02M 68.36M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
52.12M 52.65M 52.97M 54.08M 54.60M 54.80M 57.12M 59.15M 62.28M 64.53M 65.41M
Normalized Net Operating Profit after Tax (NOPAT)
-20 -21 -21 -9.56 110 -19 -30 -43 -37 -46 -54
Normalized NOPAT Margin
-471.07% -425.16% -429.14% -42.27% 69.37% -138.31% -283.71% - -600.30% -491.16% -480.86%
Pre Tax Income Margin
-625.57% -531.88% -540.05% -46.35% 71.99% -169.96% -372.70% - -802.75% -660.78% -654.32%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Stoke Therapeutics’ latest statements show a company with a strong liquidity position but continued dependence on external financing. Revenue is becoming more meaningful, yet operating expenses and cash burn remain elevated as the company advances its pipeline.

  • Substantial liquidity: As of June 30, 2026, Stoke held approximately $354.3 million in cash, short-term investments and long-term investments. This compares with roughly $282.0 million in similar resources at June 30, 2024.
  • Strong balance-sheet flexibility: Total liabilities were only $48.4 million against $394.0 million of assets, and the company reported no traditional debt balance. Current assets of $322.5 million were approximately 7.7 times current liabilities of $41.9 million.
  • Revenue has generally expanded from earlier periods: Quarterly revenue increased from $2.9 million in Q3 2022 and $4.2 million in Q1 2024 to $9.3 million in Q2 2026. Revenue also rose sequentially from $6.2 million in Q1 2026.
  • Investment income provides some support: Interest and investment income contributed $3.5 million in Q2 2026, helping offset a portion of the company’s operating deficit.
  • Financing access has remained available: Stoke raised $84.3 million through financing activities in Q1 2026, following $92.3 million in Q4 2025. These financings have helped maintain a sizable cash reserve.
  • Revenue remains volatile: Quarterly revenue has fluctuated widely, including $158.6 million in Q1 2025, $13.8 million in Q2 2025, $1.4 million in Q4 2025 and $9.3 million in Q2 2026. The unusually large Q1 2025 result appears to be a one-time or nonrecurring item, making it difficult to use as a baseline for future revenue.
  • Investment portfolio management affects reported cash flow: Investing cash flow has frequently been driven by purchases, sales and maturities of investments rather than operating performance. Q2 2026 investing activities provided $9.0 million, but this included $47.1 million of investment maturities and $36.1 million of investment purchases.
  • Operating losses remain substantial: Stoke posted a $61.6 million net loss in Q2 2026, compared with losses of $50.0 million in Q1 2026 and $23.5 million in Q2 2025. The company has reported recurring quarterly losses throughout the supplied period, apart from the restated one-time profit in Q1 2025.
  • Cash burn has accelerated: Operating cash outflow was $56.6 million in Q2 2026 and $60.6 million in Q1 2026, compared with $25.4 million in Q2 2025 and $17.5 million in Q2 2024. At the recent Q1-Q2 2026 burn rate, the company’s approximately $354 million of investment and cash resources would represent roughly six quarters of funding before considering future revenue, spending changes or additional financing.
  • Research and development spending continues to rise: R&D expense reached $49.5 million in Q2 2026, up from $25.9 million in Q2 2025 and $21.1 million in Q2 2024. Total operating expenses increased to $74.8 million, far exceeding quarterly revenue of $9.3 million.
  • Shareholder dilution is a continuing risk: Weighted-average basic shares increased from 58.4 million in Q2 2025 to 66.0 million in Q2 2026. Repeated equity financing can extend Stoke’s runway, but it also reduces existing investors’ ownership percentage and may pressure per-share value.
  • Accumulated losses are growing: Retained earnings declined to negative $609.3 million by Q2 2026 from negative $401.4 million in Q2 2025 and negative $350.3 million in Q2 2023, reflecting the company’s sustained history of losses.

Overall, Stoke’s balance sheet provides meaningful near-term financial capacity, and revenue has improved from the low levels seen in 2022 and 2023. However, the investment case remains dependent on clinical and commercial progress because rising R&D spending, recurring operating losses and continued equity financing are consuming cash and creating dilution risk.

11/17/26 01:26 AM ETAI Generated. May Contain Errors.

Stoke Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Stoke Therapeutics' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Stoke Therapeutics' net income appears to be on a downward trend, with a most recent value of -$6.89 million in 2025, rising from -$12.52 million in 2018. The previous period was -$88.98 million in 2024. Check out Stoke Therapeutics' forecast to explore projected trends and price targets.

Stoke Therapeutics' total operating income in 2025 was -$20.59 million, based on the following breakdown:
  • Total Gross Profit: $184.42 million
  • Total Operating Expenses: $205.01 million

Over the last 7 years, Stoke Therapeutics' total revenue changed from $0.00 in 2018 to $184.42 million in 2025, a change of 18,442,000,000.0%.

In the past 13 quarters, Stoke Therapeutics' cash and equivalents has ranged from $83.39 million in Q3 2025 to $274.82 million in Q1 2025, and is currently $107.27 million as of their latest financial filing in Q3 2026.

Stoke Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and none in 2018.

Over the last 7 years, Stoke Therapeutics' book value per share changed from 148.12 in 2018 to 6.17 in 2025, a change of -95.8%.



Financial statements for NASDAQ:STOK last updated on 11/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners